<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14200">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00324116</url>
  </required_header>
  <id_info>
    <org_study_id>A5751016</org_study_id>
    <nct_id>NCT00324116</nct_id>
  </id_info>
  <brief_title>Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions</brief_title>
  <official_title>A Prospective, Open-Label Multi Center Trial Evaluating The Safety And Efficacy Of 0.3 Mg/Eye Pegaptanib Sodium (Macugen) Intravitreous Injection Given Every 6 Weeks For 54 Weeks In Patients With Small Neovascular Age-Related Macular Degeneration (AMD) Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ITEC GROUP 3</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy, based on the best-corrected visual acuity (using the ETDRS chart),
      of a 0.3 mg/eye pegaptanib sodium intravitreous injection given every 6 weeks for 54 weeks
      in patients with exudative age-related macular degeneration and evidence of recent onset,
      subfoveal and/or juxtafoveal choroidal neovascularization.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS)</measure>
    <time_frame>Baseline, 54 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Responders defined as subjects having lost from baseline less than 15 letters of the best-corrected visual acuity; includes subjects with visual acuity gain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Acuity</measure>
    <time_frame>Baseline, 6 weeks, 12 weeks, 54 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Change: mean score at observation minus mean score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Gaining Vision</measure>
    <time_frame>54 weeks or at early termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects gaining vision: gain from baseline of more than 15 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Maintaining Vision</measure>
    <time_frame>54 weeks or at early termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects maintaining vision: gain from baseline of more than 0 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Severe Visual Loss</measure>
    <time_frame>54 weeks or at early termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with severe visual loss: loss from baseline of &gt;= 30 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With a Distance Visual Acuity of &gt; 20/200 at Baseline and Progressing to (&lt;= 20/200)</measure>
    <time_frame>54 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects with improving scores are those with &gt; 20/200 at Baseline and progressing to =&lt; 20/200 at Week 54.
Subjects with no change are those with &gt; 20/200 at Baseline and remaining at &gt; 20/200 at Week 54.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ 25).</measure>
    <time_frame>Baseline, 54 weeks or at early termination</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patient reported vision-related functioning and quality of life as measured using the 25 item NEI-VFQ 25. Change = Mean score at 54 weeks - mean score at baseline. A positive change represents an increase in function/health from Baseline. Items grouped as the following - Composite: mean score items 1-25; General Health: item 1; General Vision: item 2; Ocular Pain:4,19; Near Vision:5,6,7; Distance Vision:8,9,14; Social Functioning:11,13; Mental Health Activities:3,21,22,25; Role Difficulties:17,18; Dependency:20,23,24; Driving:15c,16, 16a; Color Vision: 12; Peripheral Vision: 10.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pegaptanib sodium (Macugen)</intervention_name>
    <description>0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>MACUGEN</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and angiographic evidence of juxtafoveal or subfoveal choroidal
             neovascularization secondary to AMD with a total lesion size of less than 2 MPS disc
             areas

          -  Best-corrected visual acuity in the study eye greater than 54 letters (ETDRS)

          -  Women must be using 2 forms of effective contraception

          -  Adequate hematological, renal and liver functions

        Exclusion Criteria:

          -  Any atrophy or fibrosis; any retinal hemorrhage measuring more than 1 disc area

          -  Any extrafoveal choroidal neovascularization

          -  Any intraocular surgery or thermal laser to the study eye within 3 months of
             enrollment

          -  Previous or concomitant therapy for AMD including PDT with verteporfin (Visudyne) or
             subfoveal/non-foveal thermal laser therapy, transpupillary thermotherapy, external
             beam radiation, submacular surgery.

          -  Presence of other causes of choroidal neovascularization, including pathological
             myopia, the ocular histoplasmosis syndrome, angioid streaks, choroidal rupture and
             multifocal choroiditis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Angers</city>
        <state>Cedex 09</state>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lyon</city>
        <state>Cedex 4</state>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Besancon</city>
        <state>Cedex</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Creteil</city>
        <state>Cedex</state>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Macon</city>
        <state>Cedex</state>
        <zip>71018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Poitiers</city>
        <state>Cedex</state>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Belfort Cedex</city>
        <zip>90016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>DIJON Cedex</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Rochefoucauld</city>
        <zip>16110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>La Tronche</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lille</city>
        <zip>59800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Limoges Cedex 1</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Montpellier</city>
        <zip>34070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>MULHOUSE Cedex 1</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75557</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>PARIS Cedex 19</city>
        <zip>75940</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rives</city>
        <zip>38140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint-Herblain</city>
        <zip>44819</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5751016&amp;StudyName=Evaluation%20Of%20Safety%20And%20Efficacy%20Of%200.3%20Mg/Eye%20Macugen%20In%20Patients%20With%20Small%20Age-Related%20Macular%20Degeneration%20Lesions</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2010</verification_date>
  <lastchanged_date>March 15, 2010</lastchanged_date>
  <firstreceived_date>May 8, 2006</firstreceived_date>
  <firstreceived_results_date>August 25, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer Inc</organization>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pegaptanib Sodium</title>
          <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81">subjects received treatment</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>unknown</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegaptanib Sodium</title>
          <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="81"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="76.3" spread="6.7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="47"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS)</title>
        <description>Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Responders defined as subjects having lost from baseline less than 15 letters of the best-corrected visual acuity; includes subjects with visual acuity gain.</description>
        <time_frame>Baseline, 54 Weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>The full analysis set (FAS) was derived from the set of all enrolled subjects who 1) were administered the study medication AND 2) had post-baseline documentation of efficacy available. In the case of missing data post-baseline, the subject was considered censored at the time of the last available data for the score.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Responders for Visual Acuity Using Early Treatment Diabetic Retinopathy Study (ETDRS)</title>
            <description>Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Responders defined as subjects having lost from baseline less than 15 letters of the best-corrected visual acuity; includes subjects with visual acuity gain.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Responders</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="40" lower_limit="76" upper_limit="95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Non-Responders</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Censored (subjects with missing data)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percent responders</param_type>
            <param_value>85</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>76</ci_lower_limit>
            <ci_upper_limit>95</ci_upper_limit>
            <estimate_desc>Proportion of responders estimated by Kaplan-Meier analysis. Proportion of responders along with 95% CI calculated directly from estimate of survival distribution function. Percentage denominator = total number of subjects without missing data.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Acuity</title>
        <description>Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Change: mean score at observation minus mean score at baseline.</description>
        <time_frame>Baseline, 6 weeks, 12 weeks, 54 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; n=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change From Baseline in Visual Acuity</title>
            <description>Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0. Change: mean score at observation minus mean score at baseline.</description>
            <units>score on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>6 weeks (n=76)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.29" spread="11.11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>12 weeks (n=74)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.86" spread="13.79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>54 weeks (n=49)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-11.12" spread="17.96"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>6 weeks</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-4.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.83</ci_lower_limit>
            <ci_upper_limit>-1.75</ci_upper_limit>
            <estimate_desc>95% CI for the change in mean value obtained from one sample t-test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>12 weeks</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-5.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-9.06</ci_lower_limit>
            <ci_upper_limit>-2.67</ci_upper_limit>
            <estimate_desc>95% CI for the change in mean value obtained from one sample t-test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>54 weeks</groups_desc>
            <non_inferiority>No</non_inferiority>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-11.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-16.28</ci_lower_limit>
            <ci_upper_limit>-5.96</ci_upper_limit>
            <estimate_desc>95% CI for the change in mean value obtained from one sample t-test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Gaining Vision</title>
        <description>Subjects gaining vision: gain from baseline of more than 15 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
        <time_frame>54 weeks or at early termination</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Gaining Vision</title>
            <description>Subjects gaining vision: gain from baseline of more than 15 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
            <units>participant</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Gained</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Did not gain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Assessment Not Done</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage of subjects</param_type>
            <param_value>5.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.61</ci_lower_limit>
            <ci_upper_limit>11.32</ci_upper_limit>
            <estimate_desc>Proportion of subjects gaining vision was estimated on an observed case basis. Percentage denominator = total number of subjects in the FAS. 95% confidence intervals were calculated from Fleiss quadratic equations</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Maintaining Vision</title>
        <description>Subjects maintaining vision: gain from baseline of more than 0 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
        <time_frame>54 weeks or at early termination</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Maintaining Vision</title>
            <description>Subjects maintaining vision: gain from baseline of more than 0 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Maintained</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Did not maintain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Done</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage of subjects</param_type>
            <param_value>22.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.22</ci_lower_limit>
            <ci_upper_limit>32.11</ci_upper_limit>
            <estimate_desc>Proportion of subjects maintaining vision was estimated on an observed case basis. Percentage denominator = total number of subjects in the FAS. 95% confidence intervals were calculated from Fleiss quadratic equations.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Severe Visual Loss</title>
        <description>Subjects with severe visual loss: loss from baseline of &gt;= 30 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
        <time_frame>54 weeks or at early termination</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With Severe Visual Loss</title>
            <description>Subjects with severe visual loss: loss from baseline of &gt;= 30 letters of visual acuity. Best-corrected visual acuity assessed using retroilluminated modified Ferris-Bailey ETDRS charts. When possible to measure visual acuity @ 2.0 m (≥20 letters), visual acuity score for that eye recorded as number of letters correct plus 15; otherwise, score was number of letters read correctly @ 1.0 m plus number, if any, read @ 2.0 m. If no letter was read correctly either at 2.0 or 1.0 m, then visual acuity score was recorded as 0.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Severe Loss</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not severe loss</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Not Done</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage of subjects</param_type>
            <param_value>13.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>7.39</ci_lower_limit>
            <ci_upper_limit>22.24</ci_upper_limit>
            <estimate_desc>Proportion of subjects with severe visual loss was estimated on an observed case basis. Percentage denominator = total number of subjects in the FAS. 95% confidence intervals were calculated from Fleiss quadratic equations.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With a Distance Visual Acuity of &gt; 20/200 at Baseline and Progressing to (&lt;= 20/200)</title>
        <description>Subjects with improving scores are those with &gt; 20/200 at Baseline and progressing to =&lt; 20/200 at Week 54.
Subjects with no change are those with &gt; 20/200 at Baseline and remaining at &gt; 20/200 at Week 54.</description>
        <time_frame>54 weeks</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; n=77 (number of Subjects at Baseline with &gt;20/200 Visual Acuity)</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects With a Distance Visual Acuity of &gt; 20/200 at Baseline and Progressing to (&lt;= 20/200)</title>
            <description>Subjects with improving scores are those with &gt; 20/200 at Baseline and progressing to =&lt; 20/200 at Week 54.
Subjects with no change are those with &gt; 20/200 at Baseline and remaining at &gt; 20/200 at Week 54.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Improved</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Change</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <param_type>percentage of subjects</param_type>
            <param_value>25.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>16.28</ci_lower_limit>
            <ci_upper_limit>34.81</ci_upper_limit>
            <estimate_desc>Proportion of subjects progressing to &lt;=20/200 was estimated on an observed case basis. Percentage denominator = total number of subjects in the FAS. 95% confidence intervals were calculated from Fleiss quadratic equations.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ 25).</title>
        <description>Patient reported vision-related functioning and quality of life as measured using the 25 item NEI-VFQ 25. Change = Mean score at 54 weeks - mean score at baseline. A positive change represents an increase in function/health from Baseline. Items grouped as the following - Composite: mean score items 1-25; General Health: item 1; General Vision: item 2; Ocular Pain:4,19; Near Vision:5,6,7; Distance Vision:8,9,14; Social Functioning:11,13; Mental Health Activities:3,21,22,25; Role Difficulties:17,18; Dependency:20,23,24; Driving:15c,16, 16a; Color Vision: 12; Peripheral Vision: 10.</description>
        <time_frame>Baseline, 54 weeks or at early termination</time_frame>
        <safety_issue>No</safety_issue>
        <population>FAS; n=number of subjects with evaluable data.</population>
        <group_list>
          <group group_id="O1">
            <title>Pegaptanib Sodium</title>
            <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Change in Vision-related Functioning and Quality of Life Using the National Eye Institute Visual Functioning Questionnaire-25 (NEI-VFQ 25).</title>
            <description>Patient reported vision-related functioning and quality of life as measured using the 25 item NEI-VFQ 25. Change = Mean score at 54 weeks - mean score at baseline. A positive change represents an increase in function/health from Baseline. Items grouped as the following - Composite: mean score items 1-25; General Health: item 1; General Vision: item 2; Ocular Pain:4,19; Near Vision:5,6,7; Distance Vision:8,9,14; Social Functioning:11,13; Mental Health Activities:3,21,22,25; Role Difficulties:17,18; Dependency:20,23,24; Driving:15c,16, 16a; Color Vision: 12; Peripheral Vision: 10.</description>
            <units>score on scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Composite (n=25)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.25" spread="15.71"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>General Health (n=42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.17" spread="14.52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>General Vision (n=41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.90" spread="16.26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Ocular Pain (n=43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.35" spread="15.29"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Near Vision Activities (n=43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.88" spread="27.60"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Distance Vision Activities (n=43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-6.78" spread="23.68"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Social Functioning (n=43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.58" spread="24.84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Mental Health Activities (n=43)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-0.30" spread="20.45"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Role Difficulties (n=41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.39" spread="26.46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Dependency (n=41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-5.28" spread="22.15"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Driving (n=27)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-3.70" spread="30.67"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Color Vision (n=41)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-1.83" spread="18.87"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Peripheral Vision (n=42)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-4.17" spread="25.25"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pegaptanib Sodium</title>
          <description>All subjects received a 0.3 mg/eye pegaptanib sodium intravitreous injection every 6 weeks for 54 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (v12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (v12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="81"/>
              </event>
              <event>
                <sub_title>Myodesopsia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="81"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of &lt; 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), &lt; 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.govCallCenter@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
